目前，A股行情火热，为方便选手了解到有价值的信息，方便与高手交流市场热点、投资技巧。报名了掘金大赛，就能申请加入比赛交流群，加群方法 是：点击微信主页右上角+号，选择添加朋友，然后点击企业微信联系人，输入手机号13882019385，添加企业微信火山君。 中报行情如火如荼，高手看好券商、白银板块 每经记者｜吴永久 每经编辑｜闫峰峰 本周末，美国关税谈判又出现重要消息。当地时间12日，美国总统特朗普称对墨西哥、欧盟输美商品分别征收30%关税。 近期市场热炒中报行情，工业富联带动了英伟达产业链，药明康德刺激CXO板块大涨，北方稀土刺激稀土永磁板块大涨。在每日经济新闻App举办的掘金 大赛中，第66期比赛将于明日开赛，目前多位选手积极报名。周五银行股回调拖累沪指，如何看待关税对市场的影响？下一步市场主线有哪些？今日一些 参赛高手分享了观点。 大赛为模拟炒股，模拟资金50万元。第66期比赛的报名时间为7月12日到7月18日，比赛时间为7月14日到7月18日。正收益就获奖，报名就拿福利！周周发 奖金，月月有大奖！ 每期比赛的税前现金奖励为：第1名奖励688元，第2~4名奖励188元/人，第5~10名奖励88元/人，其余 ...

事件：公司发布2025 年半年度业绩预告，预计上半年实现收入207.99 亿元（+20.64%），其中持续经营 业务收入同比增长24.24%,经调整归母净利润63.15 亿元（+44.43%），扣非归母净利润55.82 亿元 （+26.47%）。单Q2预计实现收入111.45 亿元（+20.37%），经调整归母净利润约36.37 亿元 （+47.90%），扣非净利润32.53 亿元(+36.70%)。 业绩预告超预期，Q2 收入及利润同比加速增长。上半年业绩预告较超预期，其中Q2 业绩较为亮眼。收 入端，Q2 表观增速与Q1 相近，但25H1 持续经营同比增速较25Q1 略有加速；利润端，25Q1 经调整净 利润26.8 亿元（+40%），Q2 同比增速进一步提升至47.90%，经调整净利润率达32.64%。根据历史数 据，Q1 至Q4 收入及利润逐季度提升，因此下半年季度间利润有望继续保持增长。 CDMO 板块从订单复苏逐渐转换至业绩改善。自2024H1 以来公司在手订单持续回暖，2024H1 在手订 单431 亿元，同比增长33.2%，截至2025Q1 在手订单523.3 亿元，同比增长47.1%；订单增 ...

Core Viewpoint - The CRO (Contract Research Organization) sector is experiencing a significant upward trend, driven by the strong performance forecast of WuXi AppTec, which is expected to see substantial revenue and profit growth in the first half of 2025 [1][3]. Financial Performance - WuXi AppTec anticipates revenue of approximately RMB 20.8 billion for the first half of 2025, representing a year-on-year increase of about 20.6% [3]. - The company expects a net profit attributable to shareholders of around RMB 8.56 billion, reflecting a year-on-year growth of approximately 101.9%, which includes investment income from the sale of equity in an associate [3]. - The adjusted Non-IFRS net profit is projected to be about RMB 6.31 billion, up 44.4% year-on-year, while the net profit excluding non-recurring items is expected to be around RMB 5.58 billion, a 26.5% increase [3]. Business Segments - The chemical business remains the primary revenue source for WuXi AppTec, accounting for over 70% of total revenue in recent years [4]. - The company has successfully supported the approval of multiple new drugs by the FDA and other regulatory bodies, indicating strong performance in its chemical business [4]. - The GLP-1 (glucagon-like peptide-1) drug development area is highlighted as a significant growth opportunity, with the number of clinical candidates increasing substantially [5]. Industry Trends - The Chinese pharmaceutical industry is transitioning from generic drug production to innovative drug development, which is driving demand for CRO services [2][6]. - The total licensing-out transaction amount for innovative drug companies reached USD 45.5 billion in the first five months of the year, nearing the total for the previous year [6]. - The regulatory environment is supportive of innovative drug development, with new measures introduced to enhance the quality of innovation in the pharmaceutical sector [6]. Strategic Moves - WuXi AppTec is optimizing its CGT (cell and gene therapy) business by divesting certain assets to mitigate potential risks associated with regulatory changes [7]. - The global cell and gene therapy market is projected to grow significantly, indicating a favorable environment for WuXi AppTec's strategic focus in this area [7]. Market Dynamics - The CRO sector is expected to benefit from a rebound in investment and financing within the healthcare sector, with a notable increase in financing events and amounts [8]. - However, the industry faces intense competition, with the number of qualified clinical trial institutions in China increasing significantly, leading to price pressures [8]. - Despite challenges, the demand for medical outsourcing services is recovering, and companies with global service capabilities are well-positioned to capitalize on this trend [8].

Market Overview - The market atmosphere is positive with US stocks rising and A-shares showing strength, while Hong Kong stocks experienced a slight pullback due to bank stocks [1] - The market is less concerned about tariffs as outcomes are continuously delayed or modified, with a recent report indicating that the US plans to expand copper import tariffs to include semi-finished products [1] Investment Opportunities - Goldman Sachs has raised its forecast for Asian stock markets, citing a more favorable macro environment and increased certainty in tariff policies, raising the MSCI Asia Pacific index target by 3% to 700 points, indicating a potential 9% return [2] - The China Securities Association has released new measures to enhance self-regulation and promote high-quality development in the securities industry, which may open new revenue channels for brokerages [2] Securities Industry Performance - The securities industry is experiencing a surge in performance, with a significant increase in IPO applications in the first half of the year, totaling 177 applications, a 510.3% increase year-on-year [3] - Smaller securities firms are seeing substantial gains, with companies like Zhongzhou Securities and Guolian Minsheng rising over 47% and 15% respectively [3] Insurance Sector Developments - The Ministry of Finance has issued a notice to optimize performance assessments for state-owned insurance companies, allowing for a more flexible investment strategy that could lead to increased A-share investments [4] - Major insurance companies like Sunshine Insurance and China Pacific Insurance have seen stock price increases following this announcement [4] CXO Sector Growth - WuXi AppTec reported a revenue of approximately RMB 20.8 billion for the first half of the year, a year-on-year increase of about 20.64%, with a projected annual revenue of RMB 41.5 billion to RMB 43 billion [5] - Other companies in the CXO sector, such as Kanglong Huacheng and WuXi Biologics, also reported significant stock price increases [6] Semiconductor Industry Insights - The domestic photolithography machine sector is witnessing positive changes, with advancements in immersion DUV and i-line technology, indicating a strong demand for domestic production [8] - Companies like SMIC and Hua Hong Semiconductor are positioned to benefit from the growing domestic semiconductor market [9] Shipping Industry Developments - Derxiang Shipping reported a 38.5% increase in revenue for the first quarter, driven by a rise in average freight rates [10] - The company is expanding its service network and has plans for new vessel orders, enhancing its competitive position in the market [12]

【导读】香港金管局总裁余伟文：港元拆息存在上调可能性 中国基金报记者 格林 7月11日，港股三大指数冲高回落。截至收盘，恒生指数涨0.46%，报24139.57点；恒生国企指数涨0.22%，报8687.56点；恒生科技指数涨0.61%，报 5248.48点。全日大市成交额为3239.50亿港元，南向资金净买入额为17.44亿港元。 蓝筹股方面，药明康德涨10.46%，药明生物涨3.70%；华润万象生活跌2.33%，安踏体育跌2.32%。 中州证券大涨 7月11日，中资券商股继续高歌猛进。其中，国联民生涨15.40%，恒投证券涨10.94%，国泰海通涨10.50%，中州证券更是大涨47.47%。 开源证券指出，6月，上交所新开户人数同比大幅增加，交易量同比亦显著增加。同期，债市和股市向好，券商海外业务则受益于港股市场高景气。该机 构预计上市券商中报业绩将延续一季度以来的增长势头，关注后续业绩预告、稳定币等主题对券商业绩的催化作用，继续看好券商板块。 老铺黄金降温 日前，药明康德发布截至2025年6月30日止六个月的盈利预告。预计药明康德今年上半年实现营业收入约人民币207.99亿元，同比增幅约20.64%，其中 ...

未平仓空单比（绝对值）较上一次减少最多为远东宏信（03360）、众安在线（06060）、荣昌生物 （09995），分别减少-1.62%、-1.55%、-1.32%。 前10大未平仓空仓比 | 股票名称 | 前次空仓数 | 本次空仓数 | 最新空仓比↓ | | --- | --- | --- | --- | | 药明康德(02359) | 8717.47 万股 | 8734.54 万股 | 22.57% | | 宁德时代(03750) | 2631.99 万股 | 2768.85 万股 | 17.76% | | 中远海控(01919) | 4.06 亿股 | 4.11 亿股 | 14.27% | | 赣锋锂业(01772) | 5001.51 万股 | 5166.20 万股 | 12.80% | | 山东黄金(01787) | 1.09 亿股 | 1.10 亿股 | 12.77% | | 绿叶制药(02186) | 4.62 亿股 | 4.75 亿股 | 12.64% | | 协鑫科技(03800) | 33.24 亿股 | 35.43 亿股 | 12.44% | | 万科企业(02202) | 2.80 亿股 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

智通财经APP获悉，港股早盘震荡走高，恒指及国指盘中均涨超1%，恒科指一度涨超2%，午后三大指 数涨幅则逐步收窄。截止收盘，恒生指数涨0.46%或111.2点，报24139.57点，全日成交额为3239.5亿港 元；恒生国企指数涨0.22%，报8687.56点；恒生科技指数涨0.61%，报5248.48点。全周来看，恒指累涨 0.93%，国指累涨0.91%，恒科指累涨0.62%。 华鑫证券近日指出，当前美元指数空头头寸较为拥挤，叠加降息预期交易降温，美元指数短期反弹，港 币汇率进一步承压，成为香港市场主要风险点。此外，当前港股基本面、情绪面趋势指标均转弱，外卖 大战升温拖累叠加AI叙事弱化，恒生科技调整。该行称，南向资金持续买入下，关注高韧性优质港股 资产配置机会。 蓝筹股表现 药明康德(02359)领涨蓝筹。截至收盘，涨10.46%，报88.15港元，成交额26.43亿港元，贡献恒指4.53 点。药明康德发盈喜，预计2025年上半年实现营业收入约人民币207.99亿元，同比增长约20.64%；净利 润85.61亿元，同比增长约101.92%。大和表示，基于其收入前景清晰，利润率改善，以及强劲的订单积 压，予 ...

港股收盘，恒生指数收涨0.46%，恒生科技指数收涨0.61%。中资券商股走强，中州证券(01375.HK)收 涨47%；生物医药概念大幅回升，药明康德(02359.HK)收涨10%；芯片、保险、加密货币等概念涨幅居 前。 ...

Core Viewpoint - The healthcare ETF, Taikang (159760), has shown a strong performance with a 1.51% increase, marking three consecutive days of gains, driven by significant rises in key stocks such as WuXi AppTec and Kelun Pharmaceutical [1][2]. Group 1: ETF Performance - As of July 11, 2025, the Taikang healthcare ETF reached a new high of 82.42 million yuan, the highest in three months [2]. - The index it tracks, the National Public Health and Healthcare Index (980016), rose by 1.45% [1]. Group 2: Company Performance - WuXi AppTec (603259) reported an expected adjusted net profit of approximately 6.315 billion yuan for the first half of the year, a year-on-year increase of about 44.43% [2]. - The company anticipates a net profit attributable to shareholders of approximately 8.561 billion yuan, reflecting a year-on-year growth of about 101.92% [2]. - Basic earnings per share are projected to be around 3.01 yuan, up approximately 106.16% year-on-year [2]. Group 3: Policy and Market Trends - The National Healthcare Security Administration has initiated a new round of adjustments to the national medical insurance drug catalog, indicating a favorable policy environment for innovative drugs [3]. - China ranks first globally in the number of original drugs developed by its enterprises, with increasing foreign capital investment in Chinese innovative drugs [3]. - The healthcare sector is expected to benefit from a comprehensive policy support system, enhancing the global market position of domestic innovative drugs [3]. Group 4: Index Composition - As of May 30, 2025, the top ten weighted stocks in the National Public Health and Healthcare Index accounted for 52.46% of the index, including major players like Hengrui Medicine and Mindray Medical [4].